Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Chroma Therapeutics discovers and develops novel small-molecule drugs for the treatment of common cancers and inflammatory disorders.
Gilde joined the company as one of its first investors. The company has since advanced its lead product Tosedostat®, for leukemia, to the final development stage. It has also built a product pipeline of new inflammation therapies using its proprietary cell accumulation approach, which targets the nucleus of a cell. In 2009 it began to partner with GlaxoSmithKline (GSK). Chroma Therapeutics is based in Oxford, UK.
More Chroma Therapeutics news
Chroma Therapeutics Advances Novel Targeted Agent towards Clinical Development; Receives Milestone
Chroma Therapeutics enters collaboration with Cell Therapeutics Inc
Chroma Therapeutics signs $1 billion deal with GlaxoSmithKline
Chroma Therapeutics completes £15 million Series D financing
CHROMA announces Positive Phase II Efficacy Data for Novel Cancer Therapy Tosedostat
Venture&Growth
Levicept
UK-based Therapeutics company developing a novel therapy to treat chronic pain.
Venture&Growth
Karius, Inc.
Karius is a U.S.-based diagnostic company that develops and commercializes an AI-based liquid biopsy test to diagnose serious infections in immunocompromised patients and other hospitalized patients. The company is commercial in the U.S. and provides strong potential for better care
Venture&Growth
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell
